(Q29620878)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma (English)

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=25482239

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Gordon J Freeman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Margaret A Shipp

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Alexander M Lesokhin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Stephen M Ansell

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Ivan Borrello

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Emma C Scott

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Martin Gutierrez

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Stephen J Schuster

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Michael M Millenson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Deepika Cattry

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Scott J Rodig

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Bjoern Chapuy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Azra H Ligon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Lili Zhu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Joseph F Grosso

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Su Young Kim

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

John M Timmerman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Philippe Armand

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=25482239

24 February 2020

language of work or name

1 reference

30 April 2017

publication date

6 December 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

The New England Journal of Medicine

24 February 2020

published in

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=25482239

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

372

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=25482239

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=25482239

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

311-319

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

24 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

PD-1 and its ligands in tolerance and immunity

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Toxicity and response criteria of the Eastern Cooperative Oncology Group

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

State-of-the-art therapeutics: Hodgkin's lymphoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Revised response criteria for malignant lymphoma

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

Co-expression of Epstein-Barr virus latent membrane protein and vimentin in "aggressive" histological subtypes of Hodgkin's disease

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4348009

26 November 2018

Identifiers

DOI

10.1056/NEJMOA1411087

3 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=25482239

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=25482239

3 references

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=25482239

24 February 2020

PubMed publication ID

3 references

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25482239%20AND%20SRC:MED&resulttype=core&format=json